Fiera Capital Corp Has $29.12 Million Position in Guardant Health, Inc. (NASDAQ:GH)

Fiera Capital Corp reduced its stake in Guardant Health, Inc. (NASDAQ:GHGet Rating) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 291,115 shares of the company’s stock after selling 10,849 shares during the period. Fiera Capital Corp owned about 0.29% of Guardant Health worth $29,118,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of GH. Hall Laurie J Trustee bought a new position in Guardant Health in the 4th quarter valued at approximately $30,000. National Bank of Canada FI bought a new position in Guardant Health in the 4th quarter valued at approximately $32,000. Daiwa Securities Group Inc. raised its holdings in Guardant Health by 74.4% in the 3rd quarter. Daiwa Securities Group Inc. now owns 347 shares of the company’s stock valued at $43,000 after buying an additional 148 shares during the last quarter. FourThought Financial LLC raised its holdings in Guardant Health by 1,690.0% during the 3rd quarter. FourThought Financial LLC now owns 358 shares of the company’s stock worth $44,000 after purchasing an additional 338 shares during the last quarter. Finally, Spire Wealth Management raised its holdings in Guardant Health by 274.7% during the 4th quarter. Spire Wealth Management now owns 622 shares of the company’s stock worth $62,000 after purchasing an additional 456 shares during the last quarter. Institutional investors own 90.88% of the company’s stock.

NASDAQ GH traded down $2.66 during mid-day trading on Friday, hitting $61.70. The company’s stock had a trading volume of 606,380 shares, compared to its average volume of 835,861. The company’s 50 day simple moving average is $64.26 and its 200 day simple moving average is $82.60. Guardant Health, Inc. has a twelve month low of $46.87 and a twelve month high of $161.59. The company has a debt-to-equity ratio of 1.76, a quick ratio of 5.57 and a current ratio of 5.72.

Guardant Health (NASDAQ:GHGet Rating) last posted its quarterly earnings results on Wednesday, February 23rd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.24. Guardant Health had a negative net margin of 108.57% and a negative return on equity of 53.91%. The business had revenue of $108.10 million during the quarter, compared to the consensus estimate of $98.72 million. During the same quarter last year, the firm posted ($0.94) EPS. Guardant Health’s revenue was up 38.1% compared to the same quarter last year. Sell-side analysts predict that Guardant Health, Inc. will post -4.83 earnings per share for the current fiscal year.

GH has been the subject of several analyst reports. Canaccord Genuity Group lowered their price target on shares of Guardant Health from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 24th. Wells Fargo & Company lowered their price target on shares of Guardant Health from $150.00 to $115.00 and set an “overweight” rating for the company in a report on Thursday, February 24th. SVB Leerink lowered their price target on shares of Guardant Health from $170.00 to $140.00 and set an “outperform” rating for the company in a report on Thursday, February 24th. Canaccord Genuity Group lowered their price target on shares of Guardant Health from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 24th. Finally, Citigroup lowered their price target on shares of Guardant Health from $180.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Guardant Health presently has an average rating of “Buy” and a consensus price target of $138.50.

In other Guardant Health news, Director Stanley J. Meresman sold 4,934 shares of Guardant Health stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $58.74, for a total transaction of $289,823.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 5.80% of the company’s stock.

About Guardant Health (Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Articles

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.